CT and Fluoroscopic Analyses of Valve Expansion in Redo-TAVR
JACC: Cardiovascular Interventions · 2025
DOI: 10.1016/j.jcin.2025.06.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Parasuram Krishnamoorthy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Fuster Heart Hospital, New York, New York, USA. Electronic address: parasumk@yahoo.com. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve, Multidetector Computed Tomography, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Redo transcatheter aortic valve replacement (TAVR) for transcatheter aortic valve (TAV) failure is becoming increasingly common. Although short-term outcomes appear favorable, no imaging after redo-TAVR has been performed to evaluate frame expansion and geometry. OBJECTIVES: The authors report a first-in-human experience using multidetector computed tomography (MDCT) and fluoroscopy to evaluate valve frame expansion and geometry of both index and second TAVs. METHODS: From January 2023 to April 2025, 30 of 40 consecutive patients underwent redo-TAVR for bioprosthetic valve failure and had evaluable postprocedural MDCT. Index TAVs were predilated in 80% (24 of 30), and both TAVs were postdilated in all cases for frame optimization. Frame dimensions were measured using MDCT and fluoroscopy for both index and second TAVs at different levels. Valve expansion and eccentricity were calculated by comparing observed measurements with expected nominal measurements validated from previous studies. RESULTS: TAV-in-TAV combinations were as follows: 8 of 30 (26.7%) short-in-short, 16 of 30 (53.3%) short-in-tall (15 Evolut, 1 Navitor), and 6 of 30 (20%) tall-in-short. Structural valve deterioration was the common mechanism of failure. Both MDCT and fluoroscopy showed that index TAVs were all underexpanded, and expansion was seen after redo-TAVR in all cases. The second TAVs were underexpanded across all valve types, but more so with tall-in-short (Evolut-in-SAPIEN) combination. No elevated valve gradients and no hypoattenuated leaflet thickening were observed at 30 days. CONCLUSIONS: There was significant underexpansion of both index and second TAVs after redo-TAVR, irrespective of valve type and combinations. Larger studies are needed to validate this finding and determine the longer term impact of underexpansion of the second TAV, despite acceptable short-term hemodynamic performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mount Sinai Fuster Heart Hospital, New York, New York, USA. Electronic address: parasumk@yahoo.com.
- Mount Sinai Fuster Heart Hospital, New York, New York, USA.
- Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
- Mount Sinai Fuster Heart Hospital, New York, New York, USA; Department of Cardiovascular Surgery, Mount Sinai Health System, New York, New York, USA. Electronic address: gilbert.tang@mountsinai.org.
Zitieren
APA
Krishnamoorthy, P., Onishi, T., Zaid, S., Lerakis, S., Safi, L. M., Khera, S., Hooda, A., Goel, S., Dangas, G. D., Sharma, S. K., Kini, A. S., & Tang, G. H. L. (2025). CT and Fluoroscopic Analyses of Valve Expansion in Redo-TAVR. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.06.017
Vancouver
Krishnamoorthy P, Onishi T, Zaid S, Lerakis S, Safi LM, Khera S, et al. CT and Fluoroscopic Analyses of Valve Expansion in Redo-TAVR. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.06.017
BibTeX
@article{Krishnamoorthy2025,
author = {Krishnamoorthy, Parasuram and Onishi, Takayuki and Zaid, Syed and Lerakis, Stamatios and Safi, Lucy M and Khera, Sahil and Hooda, Amit and Goel, Sunny and Dangas, George D and Sharma, Samin K and Kini, Annapoorna S and Tang, Gilbert H L},
title = {CT and Fluoroscopic Analyses of Valve Expansion in Redo-TAVR},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
doi = {10.1016/j.jcin.2025.06.017}
}
EUVIMED